WO2010050583A1 - 抗ヘリコバクター・ピロリ活性剤 - Google Patents
抗ヘリコバクター・ピロリ活性剤 Download PDFInfo
- Publication number
- WO2010050583A1 WO2010050583A1 PCT/JP2009/068668 JP2009068668W WO2010050583A1 WO 2010050583 A1 WO2010050583 A1 WO 2010050583A1 JP 2009068668 W JP2009068668 W JP 2009068668W WO 2010050583 A1 WO2010050583 A1 WO 2010050583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- helicobacter pylori
- extract
- activity
- agent
- activator
- Prior art date
Links
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 79
- 230000000694 effects Effects 0.000 title abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 48
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 31
- 241000207923 Lamiaceae Species 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 239000012190 activator Substances 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 230000035622 drinking Effects 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 244000184421 Elsholtzia ciliata Species 0.000 abstract description 7
- 241000131458 Elsholtzia Species 0.000 abstract description 4
- 244000124853 Perilla frutescens Species 0.000 abstract description 3
- 235000004348 Perilla frutescens Nutrition 0.000 abstract description 3
- 230000008029 eradication Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000006831 Elsholtzia ciliata Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000004300 Atrophic Gastritis Diseases 0.000 description 3
- 208000036495 Gastritis atrophic Diseases 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- ITWNJDOHTYFDHG-UHFFFAOYSA-N 2-methyl-4-phenylbutan-1-ol Chemical compound OCC(C)CCC1=CC=CC=C1 ITWNJDOHTYFDHG-UHFFFAOYSA-N 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N phenyl propionaldehyde Natural products CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to Helicobacter pylori involved in the development of peptic ulcer.
- the present invention relates to an anti-Helicobacter pylori activator that can effectively sterilize and eliminate Helicobacter pylori.
- Helicobacter pylori (hereinafter also referred to as Helicobacter pylori) is one of Gram-negative bacillus (Racillus) and has several edge flagella. Since this flagella rotates and moves, the name of Helicobacter (rotating fungus) is given. What is characteristic is that it can survive in the highly acidic environment of the human stomach, and as the name of H. pylori shows, it mainly infects the pylorus of the stomach.
- the present invention provides an anti-Helicobacter pylori activator useful for the treatment, prevention or amelioration of diseases related to Helicobacter pylori.
- the present inventors have found that an extract of Lamiaceae plants can effectively suppress the growth of Helicobacter pylori, and have completed the present invention.
- the present invention provides the following: 1. An anti-Helicobacter pylori activator comprising an extract of a Labiatae plant as an active ingredient, 2. The anti-Helicobacter pylori activator according to 1 above, wherein the Labiatae plant is Naginata Kouji, Aojiso, 3. The anti-Helicobacter pylori activator according to 1 above, wherein the Labiatae plant is Yahashi, 4). The anti-Helicobacter pylori activator according to any one of 1 to 3 above, wherein the extract contains a fraction that has passed through a molecular weight cutoff filter of 5,000, 5).
- a method for sterilizing Helicobacter pylori comprising eating and drinking the anti-Helicobacter pylori activator according to any one of 1 to 5 above, 6).
- the anti-Helicobacter pylori activator of the present invention has an excellent growth inhibitory action, sterilization and sterilization action against Helicobacter pylori, and is highly safe.
- the anti-Helicobacter pylori activator of the present invention has excellent thermal stability. Furthermore, the anti-Helicobacter pylori activator of the present invention can obtain a sterilizing effect in a short period of time. Therefore, it is very useful for the eradication of Helicobacter pylori and the treatment, prevention or improvement of diseases related to Helicobacter pylori.
- the anti-Helicobacter pylori activator means a composition capable of suppressing the growth of Helicobacter pylori.
- Such an anti-Helicobacter pylori activator can remove Helicobacter pylori from the stomach
- the anti-Helicobacter pylori activator of the present invention is a disease related to Helicobacter pylori, more specifically, gastric ulcer and It can be used for the treatment, prevention or improvement of peptic ulcer such as duodenal ulcer, gastritis (acute gastritis, atrophic gastritis), gastric MALT lymphoma and gastric cancer.
- the Lamiaceae plant can be any plant as long as it belongs to the family Lamiaceae, but is preferably a plant belonging to the genus Elsholtzia, more Preferable examples are Elsholtzia ciliata, Perilla frutescens viridis, and Yahashi (Elsholtzia regulosa). Naginata Koju is used as a herbal medicine. Aojiso is also widely used for food. Yahashi is commonly used as tea in China. Therefore, these extracts are highly safe and can be used for a long time.
- Dry products of Labiatae plants such as Naginata Koju and Aojiso are commercially available and can be used in the present invention.
- Yahashi for example, can be used that is native to Yunnan, China.
- the Labiatae plant used in the present invention may be in a raw state after collection or in a dried state.
- Examples of the site include mature or immature flowers, fruit, pericarp, seeds, leaves, petiole, branches, roots and the like. A flower spike is preferred.
- Extraction can be performed by a conventional extraction method, for example, by extracting an active ingredient from a plant raw material with an extraction solvent.
- the plant material may be extracted after being pulverized.
- a pulverization method a conventional method can be applied. For example, pulverization is performed using a mortar, an atomizer, a hammer mill, a stamp mill, a ball mill, or the like.
- the extraction solvent examples include water; alcohols such as methanol, ethanol, isopropanol, t-butanol, octanol, or 2-methyl-4-phenylbutanol; ketones such as acetone, methyl isobutyl ketone, acetophenone, or benzophenone.
- Esters such as ethyl acetate, butyl acetate, methyl benzoate or t-butyl benzoate; hydrocarbons such as hexane, heptane, octane, decane, undecane, dodecane, cyclohexane or decalin; phosphate buffer Buffer solutions such as physiological saline (PBS); or mixtures thereof.
- PBS physiological saline
- water, methanol, ethanol, hexane, ethyl acetate, acetone, phosphate buffered saline (PBS), or a mixture thereof is used.
- a mixed solvent of water and a hydrophilic solvent can also be used as the extraction solvent.
- the ratio of water to the hydrophilic solvent can be appropriately selected from a wide range.
- water: hydrophilic solvent 95: 5 to 5:95, preferably 50:50 to 10:90.
- a 50% ethanol aqueous solution can be used.
- Extraction is performed, for example, using 0.1 part by weight to 10,000 parts by weight, preferably 1 part by weight to 100 parts by weight of the solvent with respect to 1 part by weight of the plant body.
- the extraction temperature is not particularly limited, but is preferably 0 ° C. to 100 ° C., and more preferably 20 ° C. to 90 ° C.
- the extraction time is not particularly limited, but is preferably, for example, 1 minute to 1 week, and more preferably 30 minutes to 1 day.
- the extract can be processed by various solid-liquid separation methods such as sedimentation separation, cake filtration, clarification filtration, centrifugal filtration, centrifugal sedimentation, press separation, and filter press.
- the extract may be used after passing through a filter that cuts off a certain molecular weight.
- a fraction passing through a filter having a molecular weight of 20,000 can be preferably used, and a fraction passing through a filter having a molecular weight of 5,000 can be more preferably used.
- the extract extracted with the extraction solvent may be used as it is, or diluted or concentrated. Alternatively, it may be pulverized by a method such as freeze drying or spray drying.
- the amount of the extract used may be an effective amount that exhibits antibacterial activity against Helicobacter pylori, for example, per extract unit or per adult day, in terms of extract extract About 0.01 to 10.0 g, and about 0.1 mg to 5.0 g in terms of dry extract.
- the concentration of the extract in the preparation varies depending on the form, but in the case of solid forms such as tablets (tablets), chewable tablets, granules, capsules (eg, hard capsules), the concentration is 0.01% relative to the total mass. It is in the range of -100% by weight, preferably 10-100% by weight.
- the final concentration of the active ingredient in the stomach is adjusted to 10 to 100 ⁇ g / ml.
- the forms of the anti-Helicobacter pylori active agent of the present invention include various forms such as solid foods such as tablets (tablets), chewable tablets, granules, capsules (for example, hard capsules) and liquid foods, as well as soups, juices and teas.
- solid foods such as tablets (tablets), chewable tablets, granules, capsules (for example, hard capsules) and liquid foods, as well as soups, juices and teas.
- the anti-Helicobacter pylori activator of the present invention can also be used as a health food or a medical food, and the form is not particularly limited, but in addition to tablets (tablets), chewable tablets, granules, capsules, etc. It is preferable to make it a form that can be continuously ingested, such as foods, soups, beverages, and liquid foods.
- the anti-Helicobacter pylori activator of the present invention includes various food additives such as various nutrients, various vitamins, minerals, dietary fiber, polyunsaturated fatty acids, stabilizers such as dispersants and emulsifiers, sweeteners, Taste ingredients, flavors, etc. can be blended.
- various food additives such as various nutrients, various vitamins, minerals, dietary fiber, polyunsaturated fatty acids, stabilizers such as dispersants and emulsifiers, sweeteners, Taste ingredients, flavors, etc. can be blended.
- a liquid it may be prepared as a liquid from the beginning, but it may be prepared in a powder or paste form and dissolved in a predetermined amount of an aqueous liquid.
- the anti-Helicobacter pylori activator of the present invention can be used by adding to any food material, for example, milk, fruit juices such as orange and lemon, dairy products such as yogurt, bread and other foods.
- the anti-Helicobacter pylori activator of the present invention has excellent thermal stability. Therefore, even when added to the food and heated, the activity can be maintained.
- the anti-Helicobacter pylori activator of the present invention can remove Helicobacter pylori in the gastrointestinal tract, it can be used to treat, prevent or ameliorate diseases related to Helicobacter pylori.
- Diseases associated with Helicobacter pylori include those caused by the presence of Helicobacter pylori in the gastrointestinal tract. Specific examples include peptic ulcers such as gastric ulcer and duodenal ulcer, gastritis (acute gastritis, atrophic gastritis), gastric MALT lymphoma, gastric cancer, etc. (Helocobacter pylori infection diagnosis and treatment guidelines (revised edition), Japan Helicobacter Society, 2003). In June 2000, the Japan Helicobacter Society recommended that "Guidelines for diagnosis and treatment were published and that" all Helicobacter pylori-positive gastric ulcers and duodenal ulcers are indicated for sterilization treatment ".
- Example 1 Preparation of Extract Extract As a Lamiaceae plant, Yahashi, Naginata Kouji, Aojiso were used.
- Yahashi (Elsholtzia regulosa) was collected from Otomo, Yunnan, China, and dried plants (including flower spikes) were used.
- Elsholtzia ciliata used a commercial product of finely chopped dried whole plant (Nyakugawa Kampo Pharmacy, Neyagawa City).
- Aojiso Pier frutescens viridis was used by drying commercially available spikelets and leaves.
- Extraction was performed by stirring overnight at 4 ° C. using 30 ml of extraction solvent for 1 g of dry powder obtained by grinding dry grass in a mortar.
- As the extraction solvent PBS, 50% ethanol, and 100% methanol were used. This was centrifuged at 4,000 rpm for 30 minutes, and the supernatant was collected.
- a specimen extracted with 50% ethanol or 100% methanol was used by dissolving a dry powder obtained by evaporating alcohol in a predetermined amount of PBS and filtering it with a Millipore membrane. The PBS extract was used as it was or after being concentrated and filtered as necessary.
- Test Example 1 Measurement of anti-Helicobacter pylori activity
- the measurement of anti-Helicobacter pylori activity was carried out by a paper disc method using Viril bacteria culture agar medium (Poremedia Vi HELICO AGAR, Eiken Chemical). After the entire surface was coated with Helicobacter pylori on this medium, a thick circular paper (ADVANTEC) 8 mm in diameter soaked with 60 ⁇ l of the extract was placed thereon and cultured under 10% carbon dioxide gas. After 3 to 4 days of culture, the size of the Helicobacter pylori growth inhibition zone formed around the paper was observed. Chloramfufenicol (CM, 100 ⁇ g / ml) was placed as a positive control, and solvent PBS was placed as a negative control.
- CM Chloramfufenicol
- the minimum inhibitory concentration (MIC) of chloramphenicol according to the present method is about 5 ⁇ g / ml
- the minimum inhibitory concentration (MIC) of Helicobacter pylori in the Yahashi spikelet extract is 1 / 20 and was 0.25 ⁇ g / ml.
- the 50% ethanol extract of Yahashi Kaho had stronger anti-Helicobacter pylori activity than the PBS extract.
- the extract obtained by further extracting the residue after the extraction of Yahashi Kaho with PBS with a 50% aqueous ethanol solution has a stronger anti-Helicobacter pylori activity.
- Test Example 2 Heat stability of anti-Helicobacter pylori activity
- PBS extract of Yahashi Koho 50% ethanol extract of Naginata Koju
- Anti-Helicobacter pylori activity after heating (boiling) the PBS extract at 100 ° C. for 20 minutes was examined. The measurement was performed in the same manner as in Test Example 1 above.
- the heat-treated extract maintained almost the same level of anti-Helicobacter pylori activity as the extract before the heat treatment.
- Test Example 3 Examination of molecular size of substance having anti-Helicobacter pylori activity The molecular size of the antibacterial substance contained in the extract was examined. Yahashi's PBS extract, Naginata Koju's 50% ethanol extract and Aojiso's PBS extract were used, which were respectively 30,000, 20,000, 10,000, The antibacterial activity was measured by passing through a 5,000 molecular weight cut filter. The measurement was performed in the same manner as in Test Example 1 above.
- Test Example 4 Search for Anti-Helicobacter pylori Active Ingredients of Yahashi Using an extract extracted from Yahashi Kaho with 100% methanol, an attempt was made to separate and purify antibacterial substances. First, a 100% methanol extract of Yahashi Kaho was concentrated and then extracted with hexane, ethyl acetate, and PBS, respectively, using partition chromatography. Among these extracts, strong antibacterial activity was observed in hexane and ethyl acetate fractions. Next, the ethyl acetate fraction that showed particularly strong activity was further applied to a silica gel cartridge column.
- the anti-Helicobacter pylori activator according to the present invention has an excellent growth inhibitory action, sterilization and sterilization action against Helicobacter pylori, and has an excellent thermal stability.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
(Helicobacter pylori)を効果的に除菌・排菌することができる、抗ヘリコバクター・ピロリ活性剤に関する。
1.シソ科植物の抽出物を有効成分として含む、抗ヘリコバクター・ピロリ活性剤、
2.シソ科植物が、ナギナタコウジュ、アオジソである、上記1に記載の抗ヘリコバクター・ピロリ活性剤、
3.シソ科植物が、ヤハシである、上記1に記載の抗ヘリコバクター・ピロリ活性剤、
4.抽出物が、5,000の分子量カットオフフィルターを通過した画分を含む、上記1~3のいずれかに記載の抗ヘリコバクター・ピロリ活性剤、
5.ヘリコバクター・ピロリに関連する疾患の治療、予防または改善に用いる、上記1~4のいずれかに記載の抗ヘリコバクター・ピロリ活性剤、
6.上記1~5のいずれかに記載の抗ヘリコバクター・ピロリ活性剤を飲食することからなる、ヘリコバクター・ピロリの除菌方法、
6.シソ科植物の抽出物を含む、ヘリコバクター・ピロリ除菌のための食品添加用組成物、
に関する。
10:90である。例えば、50%エタノール水溶液を用いることができる。
シソ科植物として、ヤハシ、ナギナタコウジュ、アオジソを用いた。ヤハシ(Elsholtzia regulosa)は、中国雲南省大桃で採取され、乾燥した植物体(花穂を含む)を用いた。ナギナタコウジュ(Elsholtzia ciliata)は、乾燥させた花期の全草を細かく刻んだ市販品を使用した(百花園漢方薬局、寝屋川市)。アオジソ(Perilla frutescens viridis)は、市販されている花穂および葉を乾燥させて用いた。
抗ヘリコバクター・ピロリ活性の測定は、ビロリ菌培養寒天培地(ポアメディアVi HELICO AGAR、栄研化学)を用いたペーパーディスク法により行った。この培地にヘリコバクター・ピロリを全面塗布したのち、その上に60μlの抽出液をしみ込ませた直径8mmの厚手の円形ロ紙(ADVANTEC)を置き、10%炭酸ガス下で培養を行った。培養3~4日後に、ロ紙の周囲に形成されるヘリコバクター・ピロリ増殖阻止帯の大きさを観察した。陽性対照としてクロラムフフェニコール(CM、100μg/ml)を置き、陰性対照として溶媒であるPBSを置いた。
(1)ヤハシ抽出物
ヤハシ花穂のPBS抽出液は、強い抗ヘリコバクター・ピロリ活性があることが認められた。ヘリコバクター・ピロリの発育阻止域の大きさで判断して、ヤハシ花穂抽出液の抗ヘリコバクター・ピロリ活性は、クロラムフェニコールの100μg/ml濃度にほぼ相当する強さであった。クロラムフェニコールによる抗菌活性は5μg/ml濃度でほぼ認められなくなった。本法によるクロラムフェニコールの最小発育阻止濃度(MIC)を
5μg/ml程度と仮定すると、ヤハシ花穂抽出液のヘリコバクター・ピロリに対する最小発育阻止濃度(MIC)は、クロラムフェニコールに対し1/20であり、0.25μg/mlであった。
さらに、ヤハシ花穂の50%エタノール抽出液は、PBS抽出液より強い抗ヘリコバクター・ピロリ活性があった。また、ヤハシ花穂のPBS抽出を行った後の残渣をさらに50%エタノール水溶液で抽出した抽出液は、さらに強い抗ヘリコバクター・ピロリ活性を有することが認められた。
(2)ナギナタコウジュ抽出物
ナギナタコウジュ全草のPBS抽出液は、5倍濃縮液で明らかな抗ヘリコバクター・ピロリ活性が確認された。また、ナギナタコウジュ全草の50%エタノール抽出液および100%メタノール抽出液は、PBS抽出液より強い抗ヘリコバクター・ピロリ活性があった。
(3)アオジソ抽出物
アオジソ花穂のPBS抽出液には、濃縮することなしに強い抗ヘリコバクター・ピロリ活性が認められた。このアオジソ花穂PBS抽出液の抗ヘリコバクター・ピロリ活性は、クロラムフェニコールの100μg/ml濃度の活性を上回った。また、アオジソ花穂の50%エタノール抽出液は、PBS抽出液と同等の抗ヘリコバクター・ピロリ活性を有することが認められた。
抗ヘリコバクター・ピロリ活性を有する物質の熱安定性を検討するために、ヤハシ花穂のPBS抽出液、ナギナタコウジュの50%エタノール抽出液、およびアオジソ花穂のPBS抽出液を100℃で20分間加熱(煮沸)処理した後の抗ヘリコバクター・ピロリ活性を検討した。測定は、上記試験例1と同様の方法で行った。
いずれの抽出液において、加熱処理をした抽出液は、加熱処理前の抽出液とほぼ同程度の抗ヘリコバクター・ピロリ活性を維持した。
抽出液に含まれる抗菌物質の分子サイズを検討した。ヤハシのPBS抽出液、ナギナタコウジュ花穂の50%エタノール抽出液、アオジソのPBS抽出液を用い、これらを各々30,000、20,000、10,000、
5,000の分子量カットフィルターを通過させ、その抗菌活性を測定した。測定は、上記試験例1と同様の方法で行った。
いずれの抽出液において、分子量5,000以下の画分に強い抗ヘリコバクター・ピロリ活性が認められた。アオジソのPBS抽出液においては、分子量5,000を超える画分には抗ヘリコバクター・ピロリ活性が認められなかった。
ヤハシ花穂から100%メタノールで抽出した抽出液を用い、抗菌物質の分離・精製を試みた。先ず、ヤハシ花穂の100%メタノール抽出液を濃縮後、分配クロマトグラフィーを用いて、各々ヘキサン、酢酸エチル、PBSで抽出した。これら抽出液のうち、強い抗菌活性が認められたのはヘキサン、酢酸エチル画分であった。次に、特に強い活性を示した酢酸エチル画分をさらにシリカゲルカートリッジカラムにかけた。クロロホルム・メタノール溶液で溶出されたフラクションA1~A10(Fr.A1-Fr.A10)のうち、Fr.A5とFr.A10(クロロホルム:メタノール=4:1)に抗菌活性が認められた。この2画分を集め、さらにODSカートリッジカラムでメタノール抽出を行った。活性の認められたフラクションB1(Fr.B1)を分取用HPLCカラムで精製し、得られたフラクションC1~C99(Fr.C1-Fr.C99)について検討したところ、Fr.C10-C12に抗菌活性が認められた。これらの分離・精製の結果から、抗ピロリ菌物質は、ヘキサンや酢酸エチルのような有機溶媒によって容易に抽出される極性の高い疎水性物質であると判断された。
Claims (7)
- シソ科植物の抽出物を有効成分として含む、抗ヘリコバクター・ピロリ活性剤。
- シソ科植物が、ナギナタコウジュ、アオジソである、請求項1に記載の抗ヘリコバクター・ピロリ活性剤。
- シソ科植物が、ヤハシである、請求項1に記載の抗ヘリコバクター・ピロリ活性剤。
- 抽出物が、5,000の分子量カットオフフィルターを通過した画分を含む、請求項1~3のいずれかに記載の抗ヘリコバクター・ピロリ活性剤。
- ヘリコバクター・ピロリに関連する疾患の治療、予防または改善に用いる、請求項1~4のいずれかに記載の抗ヘリコバクター・ピロリ活性剤。
- 請求項1~5のいずれかに記載の抗ヘリコバクター・ピロリ活性剤を飲食することからなる、ヘリコバクター・ピロリの除菌方法。
- シソ科植物の抽出物を含む、ヘリコバクター・ピロリ除菌のための食品添加用組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09823693.8A EP2351572B1 (en) | 2008-10-30 | 2009-10-30 | Agent having anti-helicobacter pylori activity |
CN200980143318.2A CN102215852B (zh) | 2008-10-30 | 2009-10-30 | 抗幽门螺杆菌活性剂 |
JP2010535847A JP5600067B2 (ja) | 2008-10-30 | 2009-10-30 | 抗ヘリコバクター・ピロリ活性剤 |
US13/126,770 US8658226B2 (en) | 2008-10-30 | 2009-10-30 | Agent having anti-Helicobacter pylori activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008279358 | 2008-10-30 | ||
JP2008-279358 | 2008-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010050583A1 true WO2010050583A1 (ja) | 2010-05-06 |
Family
ID=42128942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/068668 WO2010050583A1 (ja) | 2008-10-30 | 2009-10-30 | 抗ヘリコバクター・ピロリ活性剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8658226B2 (ja) |
EP (1) | EP2351572B1 (ja) |
JP (1) | JP5600067B2 (ja) |
CN (1) | CN102215852B (ja) |
WO (1) | WO2010050583A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016029897A (ja) * | 2014-07-25 | 2016-03-07 | 木村 由美子 | しそ飲料の製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL429184A1 (pl) * | 2018-04-13 | 2019-10-21 | Ośrodek Badawczo-Produkcyjny Politechniki Łódzkiej Ichem Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja zawierająca mieszaninę ekstraktów roślinnych do wspomagania aktywności monocytów oraz komórek naturalnie cytotoksycznych (NK) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH115745A (ja) * | 1997-06-13 | 1999-01-12 | Agency Of Ind Science & Technol | 抗hiv活性物質およびその製造方法 |
JP2001270835A (ja) * | 2000-03-15 | 2001-10-02 | Korea Yakult Co Ltd | 胃潰瘍の予防及び治療に効果的な蘇葉抽出物とその用途及びその抽出物からベルベリンを得る工程 |
JP2003252776A (ja) * | 2002-02-27 | 2003-09-10 | Wakunaga Pharmaceut Co Ltd | キサンチンオキシダーゼ阻害剤 |
WO2008133098A1 (ja) * | 2007-04-16 | 2008-11-06 | Kikuji Yamaguchi | ヘリコバクター・ピロリ除菌剤 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2947646C2 (de) * | 1978-11-28 | 1984-12-20 | Kitasato Kenkyusho, Tokio/Tokyo | Substanz mit Interferon induzierender Aktivität, Verfahren zu ihrer Herstellung und ihre Verwendung |
JPS5978646A (ja) * | 1982-10-25 | 1984-05-07 | Shoichi Ando | 抹茶 |
JPS60237961A (ja) * | 1984-05-10 | 1985-11-26 | Iwasaki Shokuhin Kogyo:Kk | 特殊麺汁の製造法 |
JPS63207360A (ja) * | 1987-02-24 | 1988-08-26 | Masato Komachi | うにみその製法 |
JPH04158737A (ja) * | 1990-10-19 | 1992-06-01 | Kazumi Chiba | 生青ジソに復元可能な乾燥青ジソの製造方法 |
JPH06133744A (ja) * | 1992-10-27 | 1994-05-17 | Sumiko Sawabe | はとむぎ健康茶及びその製造方法 |
JP3547782B2 (ja) * | 1993-12-28 | 2004-07-28 | ロート製薬株式会社 | 抗ヘリコバクター・ピロリ活性剤 |
JPH08295632A (ja) * | 1995-03-02 | 1996-11-12 | Takeda Chem Ind Ltd | 抗菌剤 |
EP0821967A1 (en) * | 1996-08-02 | 1998-02-04 | Institute For Advanced Skin Research Inc. | Composition for enhancing hyaluronic acid productivity and method for preparing same |
JP3047100B2 (ja) * | 1997-09-04 | 2000-05-29 | 有限会社吉川農園 | 青臭みのないシソジュースの製造方法 |
US20010024664A1 (en) * | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
JP2002262811A (ja) * | 2001-03-08 | 2002-09-17 | Emiko Watanabe | 梅干しと植物入り豆腐、厚揚げ |
KR20070091391A (ko) * | 2006-03-06 | 2007-09-11 | 권태국 | 기능성 발효 버블음료 |
JP3977724B2 (ja) * | 2001-11-06 | 2007-09-19 | ロート製薬株式会社 | 医薬組成物 |
KR100496146B1 (ko) * | 2002-06-12 | 2005-06-20 | 주식회사 뉴로넥스 | 감초, 강황 및 소엽의 추출물을 함유한 위염 및 위궤양의예방 및 치료를 위한 조성물 |
JP2006223143A (ja) * | 2005-02-16 | 2006-08-31 | Kyoei:Kk | 香気性苦汁組成物 |
WO2007007958A1 (en) * | 2005-07-08 | 2007-01-18 | Yuhan Corporation | Herbal pharmaceutical composition for regenerative agent of cartilaginous tissue and treatment of osteoarthritis |
CN1785238A (zh) * | 2005-09-30 | 2006-06-14 | 昆明金殿制药有限公司 | 鸡肝散提取物总黄酮在制备抗炎药物中的应用 |
TWI449786B (zh) * | 2007-06-14 | 2014-08-21 | Suntory Holdings Ltd | Safflower and natural aroma of distilled liquor and its manufacturing method |
-
2009
- 2009-10-30 WO PCT/JP2009/068668 patent/WO2010050583A1/ja active Application Filing
- 2009-10-30 US US13/126,770 patent/US8658226B2/en active Active
- 2009-10-30 EP EP09823693.8A patent/EP2351572B1/en not_active Not-in-force
- 2009-10-30 JP JP2010535847A patent/JP5600067B2/ja not_active Expired - Fee Related
- 2009-10-30 CN CN200980143318.2A patent/CN102215852B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH115745A (ja) * | 1997-06-13 | 1999-01-12 | Agency Of Ind Science & Technol | 抗hiv活性物質およびその製造方法 |
JP2001270835A (ja) * | 2000-03-15 | 2001-10-02 | Korea Yakult Co Ltd | 胃潰瘍の予防及び治療に効果的な蘇葉抽出物とその用途及びその抽出物からベルベリンを得る工程 |
JP2003252776A (ja) * | 2002-02-27 | 2003-09-10 | Wakunaga Pharmaceut Co Ltd | キサンチンオキシダーゼ阻害剤 |
WO2008133098A1 (ja) * | 2007-04-16 | 2008-11-06 | Kikuji Yamaguchi | ヘリコバクター・ピロリ除菌剤 |
Non-Patent Citations (3)
Title |
---|
"Diagnosis and Treatment Guidelines for Helicobacterpylori Infection", 2003, THE JAPANESE SOCIETY FOR HELICOBACTER RESEARCH |
"Diagnosis and Treatment Guidelines", June 2000, THE JAPANESE SOCIETY FOR HELICOBACTER RESEARCH |
See also references of EP2351572A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016029897A (ja) * | 2014-07-25 | 2016-03-07 | 木村 由美子 | しそ飲料の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2351572A1 (en) | 2011-08-03 |
CN102215852B (zh) | 2014-06-11 |
CN102215852A (zh) | 2011-10-12 |
JP5600067B2 (ja) | 2014-10-01 |
EP2351572A4 (en) | 2014-09-10 |
EP2351572B1 (en) | 2018-05-16 |
US8658226B2 (en) | 2014-02-25 |
JPWO2010050583A1 (ja) | 2012-03-29 |
US20110206791A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003251197B9 (en) | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | |
Shaikh et al. | Prospective role in treatment of major illnesses and potential benefits as a safe insecticide and natural food preservative of mint (Mentha spp.): a Review | |
KR101615199B1 (ko) | 숙취해소 및 간 보호기능 개선용 건강기능성 조성물, 이를 포함하는 건강기능성 식품 및 식품첨가제 | |
JP5110673B2 (ja) | リパーゼ阻害剤 | |
WO2009153989A1 (ja) | ユーカリ抽出物の調製方法 | |
JP2007077122A (ja) | 炎症性腸疾患予防剤 | |
JP5600067B2 (ja) | 抗ヘリコバクター・ピロリ活性剤 | |
JP2007131568A (ja) | 免疫賦活剤及びこれを含有する免疫賦活性飲食物 | |
JP2006265118A (ja) | アカテツ科植物抽出物を含む抗菌剤および抗菌性組成物 | |
JP3547835B2 (ja) | 喉炎症・溶血毒の予防・治療剤およびこれを含有する口腔用組成物 | |
KR101692889B1 (ko) | 두메닥나무 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
KR20190101063A (ko) | 천연물질 추출물을 함유하는 기관지 질환 예방 및 개선을 위한 조성물 및 그 제조방법 | |
JP3858054B2 (ja) | オリーブまんでがん利用法および抗ピロリ菌活性を有する食品 | |
JP4541662B2 (ja) | 抗ピロリ菌組成物 | |
JPH10179157A (ja) | クロロフィラーゼ抑制剤、それを含む食品、飼料及び化粧料 | |
Idrus | The Role of Sapodilla Fruit on Salmonella Typhi | |
WO2005032542A1 (ja) | 空胞化毒素中和剤 | |
JP2005068081A (ja) | 発癌予防剤 | |
Sahoo | Antioxidant &antimicrobial efficacy of Ficus religiosa L. & Ficus benghalensis L. PLANT | |
JP2006188442A (ja) | ブナ科植物種子抽出物を含む抗菌剤および抗菌性組成物 | |
Coolborn et al. | HYPTIS SUAVEOLENS L. LEAF EXTRACTS IN TRADITIONAL HEALTH CARE SYSTEMS | |
WO2012117969A1 (ja) | 抗炎症剤及びその製造方法 | |
JP2024061935A (ja) | プラーク形成抑制剤 | |
JP2024026712A (ja) | 免疫賦活剤 | |
WO2007136084A1 (ja) | シックハウス症候群の症状改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980143318.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09823693 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010535847 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13126770 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009823693 Country of ref document: EP |